A. Dunkler

发表

Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.

T. Merigan, M. Winters, J. Balzarini, 1999, The Journal of infectious diseases.

Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1

R. Esnouf, E. De Clercq, A. Vandamme, 1997, Journal of virology.